ERNA

$0.27-0.00 (-1.59%)

Market ClosedAs of Mar 20, 8:00 PM UTC

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPROTranscriptsPROStatementsPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$0.27
Potential Downside
1796546.8%
Whystock Fair Value$-4773.16
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cy...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$7.20M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
0.00
Beta
High-beta play. Expect amplified moves vs. the broad market.
6.87
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-513.75%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.58

Recent News

Associated Press Finance
Oct 29, 2025

BC-Most Active Stocks

YY Group Holdings Ltd. 56,330,377 0.4678

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Aug 15, 2025

Ernexa Therapeutics First Half 2025 Earnings: US$2.91 loss per share (vs US$33.78 loss in 1H 2024)

NasdaqCM:ERNA 1 Year Share Price vs Fair Value Explore Ernexa Therapeutics's Fair Values from the Community and select...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
TipRanks
Jun 11, 2025

Ernexa Therapeutics announces 1-for-15 reverse stock split

Ernexa Therapeutics (ERNA) announced a reverse stock split of its issued and outstanding shares of common stock, par value $0.005 per share at a ratio of 1-for-15, effective June 12, 2025 at 12:01 a.m. Eastern Time. The Company’s Common Stock is expected to begin trading on a split-adjusted basis when the market opens on June 12, 2025, under the existing trading symbol “ERNA.” The Company is effecting the reverse split to regain compliance with the $1.00 minimum bid price required for continued

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.